Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment

Researchers investigate the spatial organization of cancer cells and the tumor microenvironment.

HF-158K1 by HighField Biopharmaceuticals for Bladder Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Bladder Cancer.

July 6, 2024

Duke-NUS scientist awarded major funding to develop therapeutics for chronic inflammation

Associate Professor Lena Ho from Duke-NUS Medical School has been awarded US$1.85 million (approx. S$2.51 million) to further her team’s research in developing microproteins into

July 29, 2024

Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders – Biotech Investments

Evolva Holding SA / Key word(s): Disposal 21-Nov-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

November 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.